{
    "id": 17832,
    "fullName": "BIRC5 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "BIRC5 positive indicates the presence of the BIRC5 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 332,
        "geneSymbol": "BIRC5",
        "terms": [
            "BIRC5",
            "API4",
            "EPR-1"
        ]
    },
    "variant": "positive",
    "createDate": "02/10/2016",
    "updateDate": "11/30/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 4436,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LQZ-7F treatment in acute myeloid leukemia cells expressing Birc5 resulted in decreased cell survival in culture (PMID: 26744521).",
            "molecularProfile": {
                "id": 18137,
                "profileName": "BIRC5 positive"
            },
            "therapy": {
                "id": 3506,
                "therapyName": "LQZ-7F",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4545,
                    "pubMedId": 26744521,
                    "title": "Effective Targeting of the Survivin Dimerization Interface with Small-Molecule Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26744521"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14225,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, SurVaxM (SVN53-67/M57-KLH) treatment resulted in a 6-month progression-free survival rate of 96.3% (53/55) measured from diagnosis and 62.8% (27/43) from first immunization, and an overall survival rate at 12 months of 90.9% (30/33) from diagnosis and 70.8% (17/24) from first immunization in patients with newly diagnosed glioblastoma with median tumor Birc5 (survivin) expression of 12% (J Clin Oncol 36, 2018 (suppl; abstr 2041); NCT02455557).",
            "molecularProfile": {
                "id": 18137,
                "profileName": "BIRC5 positive"
            },
            "therapy": {
                "id": 7049,
                "therapyName": "SurVaxM",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11549,
                    "pubMedId": null,
                    "title": "Phase II trial of SurVaxM combined with standard therapy in patients with newly diagnosed glioblastoma.",
                    "url": "http://abstracts.asco.org/214/AbstView_214_220133.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 4435,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LQZ-7F treatment in lung cancer cells expressing Birc5 resulted in decreased cell survival in culture (PMID: 26744521).",
            "molecularProfile": {
                "id": 18137,
                "profileName": "BIRC5 positive"
            },
            "therapy": {
                "id": 3506,
                "therapyName": "LQZ-7F",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4545,
                    "pubMedId": 26744521,
                    "title": "Effective Targeting of the Survivin Dimerization Interface with Small-Molecule Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26744521"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8543,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line harboring an NRAS mutation and positive for BIRC5 demonstrated greater sensitivity to the combination treatment of Mekinist (trametinib) and Ibrance (palbociclib) in culture compared to treatment with either agent alone (PMID: 27488531).",
            "molecularProfile": {
                "id": 26353,
                "profileName": "BIRC5 pos NRAS mut"
            },
            "therapy": {
                "id": 1368,
                "therapyName": "Palbociclib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6683,
                    "pubMedId": 27488531,
                    "title": "An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27488531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 18137,
            "profileName": "BIRC5 positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26353,
            "profileName": "BIRC5 pos NRAS mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}